Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Clin Cancer Res. 2019 Oct 15;26(2):419–427. doi: 10.1158/1078-0432.CCR-18-4212

Figure 4.

Figure 4.

A) Six chondrosarcomas demonstrate TERT (NM_198253) and ATRX (NM_000489) mutations. B) Five cases are concurrent with IDH1 mutation while all cases are concurrent with CDKN2A/2B deletion or TP53 mutation. One case of ATRX missense mutation (p.D1925N) is wild-type for IDH1/IDH2. The co-occurrence of IDH1/IDH2 mutation with TERT/ATRX alterations is statistically significant (p=0.02).